Business ❯ Pharmaceuticals ❯ Drug Development

Licensing Agreements

Zaltenibart Chronic Obstructive Pulmonary Disease (COPD) BioNTech International Licensing Clinical Trials Glenmark Pharmaceuticals Immune-mediated Diseases Multiple Sclerosis Bofanglutide Heart Disease

4 ARTICLES

3mo ago

Lilly Secures Global Rights to Hanmi’s Sonefpeglutide

The agreement gives Lilly exclusive development and commercial control outside Korea, with Hanmi taking a $75 million up‑front payment and large milestone and royalty upside.

3 ARTICLES

5mo ago

JW Pharmaceutical Licenses Korean Rights to Gan & Lee’s GLP-1 Drug in Deal Worth Up to $81 Million

3 ARTICLES

8mo ago

Lupin Strikes Semaglutide Licensing Deal With Galenicum Covering 23 Countries

5 ARTICLES

9mo ago

Crescent, Kelun-Biotech Trade Cancer Asset Rights in Cross-Border Deal as Crescent Secures $185 Million

9 ARTICLES

11mo ago

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

5 ARTICLES

11mo ago

Zenas BioPharma Licenses InnoCare’s Orelabrutinib in Autoimmune Deal Topping $2 Billion

4 ARTICLES

last yr.

Glenmark Strikes Exclusive Deal With Hengrui for Next‑Gen HER2 ADC, Paying $18 Million Upfront

8 ARTICLES

last yr.

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets

11 ARTICLES

last yr.

Glenmark Stock Hits Record High on $700 Million AbbVie Cancer Drug Deal

4 ARTICLES

last yr.

Bristol Myers Squibb and BioNTech partner on $11 billion bispecific antibody cancer drug